Navigation Links
Mission Pharmacal Acquires Eletone Cream from Ferndale Healthcare, Inc.
Date:2/3/2012

SAN ANTONIO, Feb. 3, 2012 /PRNewswire/ -- Mission Pharmacal Company recently acquired the prescription barrier cream Eletone® Cream, from Ferndale Healthcare, Inc. of Ferndale, Michigan.  Eletone Cream is a non-steroidal, barrier cream approved by the Food and Drug Administration for the long term treatment of atopic dermatitis, an inflammatory, chronically relapsing, non-contagious and pruritic or itchy skin disorder.

While the addition of Eletone Cream will strengthen Mission's pediatric product offerings, it also enhances the company's targeted expansion in the dermatology market.  To augment and support its sales efforts, Mission has also created a dermatology focused sales team.  In addition to promoting Eletone, this team will be promoting and selling three other dermatology products, Ovace®, Avar®, and Texacort®.  This new team was launched through Alamo Pharma Services, a recently introduced wholly owned subsidiary of Mission Pharmacal, established to provide increased operational and human resources support. 

"Mission Pharmacal's recent advancements in dermatology and pediatrics provide a perfect platform for the promotion of Eletone Cream," states Terry Herring, president of Mission Pharmacal's Commercial Operations.  "This product has an established market share and solid brand identity.  Our intention is to use the Mission dermatology sales team to support this and other dermatology focused products over time."

"From a pure business perspective, the strategic acquisition of Eletone Cream demonstrates Mission's commitment to our core therapeutic areas," notes Neill Walsdorf, Jr., president of Mission Pharmacal Company.  "It adds a product that can be promoted by both our pediatric and dermatology sales teams."

About Mission Pharmacal

Mission Pharmacal is a privately held pharmaceutical company based in San Antonio, Texas.  For more tha
'/>"/>

SOURCE Mission Pharmacal
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Indevus Announces Submission of New Drug Application
2. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
3. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
4. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
5. Game Commission Announces EHD Confirmed in Fayette County
6. Test for Life Commends North Carolina Rules Commission for Implementing CDC Recommendations for HIV Testing
7. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
8. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
9. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
10. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
11. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... has received an AB therapeutic equivalent rating from the ... approved New Drug Application (NDA) for testosterone gel 1.0%. ... to [AbbVie,s] AndroGel 1% and can be substituted with ... clinical effect and safety profile as AndroGel 1% when ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... "Machine Health Monitoring Market by Product, Component, Application ... report to their offering. ... monitoring market is expected to witness a moderate growth ... Europe have almost reached the saturation levels. ...
(Date:7/24/2014)... /PRNewswire-iReach/ -- Delivery of the Report will take ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... survey on Global and Chinese Hemodialysis Machine industry. ... Hemodialysis Machine including its classification, application and manufacturing ... top manufacturers of Hemodialysis Machine listing their product ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
(Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) ... various sub-segments with an in-depth analysis and forecasting ... restraints for this market with insights on trends, ... tables and 36 figures spread through 157 pages ... Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early ...
(Date:7/24/2014)... Amy Norton HealthDay Reporter THURSDAY, ... teenage boy may be dead wrong, according to a small study ... In interviews with 33 boys between the ages of 14 and ... a girl for the closeness and trust. Very few boasted about ... a relationship with a girl. "In our culture, we have ...
(Date:7/24/2014)... Pools and beaches are the place to be ... especially for small children, so Amica Insurance is ... the Centers for Disease Control and Prevention, children between the ... water-related injuries and deaths. It’s important to know the best ... is offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Drinking caffeine ... affect roughly two-thirds of women as they go through ... are preliminary, our study suggests that limiting caffeine intake ... bothersome hot flashes and night sweats," said researcher Dr. ... the Mayo Clinic in Rochester, Minn. But caffeine ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
... Inc. (Nasdaq and SWX: BMRN) today announced that,Jean-Jacques ... a,conference call and webcast on Tuesday, February 26, ... quarter and full year 2007 financial results., ... International Dial-in Number: 617.597.5312 Participant ...
... Present at Merrill Lynch,s Global Pharmaceutical Conference Feb. ... ... today that it will host a conference call and live webcast on,Wednesday, Feb. ... nine months ended Dec. 31, 2007. The Company also will provide,an operational and ...
... Mrs. Bojan M. Kuure, of,Jakobstad, Finland, has ... for her outstanding contributions and achievements in the,field ... About Mrs. Bojan M. Kuure, Mrs. ... a dedicated registered,nurse. She obtained a Special Registered ...
... Feb. 5 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the company expects to initiate shipments of,alendronate sodium ... dosage strengths when,Fosamax(R) loses market exclusivity, which is ... February 6, 2008. Alendronate sodium is the generic,version ...
... Feb. 5 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... cancer, announced today that it will,host a conference ... Time on,Tuesday, February 19, 2008 to discuss the ... A press release will be issued before the ...
... Youth may be more,likely victimized while using instant messenger ... new research this week reports., The study, conducted ... Kids and Kimberly Mitchell of the University of New,Hampshire, ... youth are most likely,to experience sexual solicitation and harassment. ...
Cached Medicine News:Health News:BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET) 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Bojan M. Kuure Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Watson to Distribute Alendronate Tablets 2Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2Health News:Are Social Networking Sites Endangering Young Teens? Study Finds Maybe Not 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: